Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells $367,870.91 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares in the company, valued at $6,238,497.40. This trade represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $35.49 on Friday. Hims & Hers Health, Inc. has a 12-month low of $23.97 and a 12-month high of $72.98. The firm has a market capitalization of $8.08 billion, a price-to-earnings ratio of 65.72, a price-to-earnings-growth ratio of 7.03 and a beta of 2.41. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The firm has a 50 day moving average of $41.85 and a 200 day moving average of $48.49.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. During the same quarter in the previous year, the business posted $0.32 earnings per share. The firm’s revenue was up 49.2% on a year-over-year basis. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has authorized a stock buyback plan on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 3% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers announced a roughly US$200 million investment to expand its New Albany, Ohio operations — a move reporters say could quietly redefine its core strategy by expanding fulfillment/operational capacity and creating ~400 jobs. Investors often view large, strategic capacity investments as potential drivers of revenue growth and margin improvement over time. Is Hims & Hers Health’s US$200 Million Ohio Bet Quietly Redefining Its Core Strategy (HIMS)?
• Positive Sentiment: The company has an active share-repurchase program — the board authorized up to $250M (about 3% of shares) — which can support the stock by reducing float and signaling management confidence in valuation. Hims, Block, and NRG Just Launched Huge Stock Buybacks
• Neutral Sentiment: Analyst / media cautions: a Zacks piece flagged HIMS among high-growth medtech/telehealth names that could slow in 2026 — a reminder that momentum names carry execution and multiple-compression risk. 3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026
• Neutral Sentiment: Large institutional ownership remains significant (e.g., Farallon, Invesco increased stakes), which can stabilize share demand but also concentrate price action; this is background context for liquidity and investor flows. HIMS company page (MarketBeat)
• Negative Sentiment: Several insiders sold shares on Dec. 17 (including Deborah Autor, Irene Becklund, Patrick Carroll and COO Michael Chi) — transactions together total roughly $1.4M+ and include large percentage reductions for some insiders. Concentrated insider selling, particularly from senior executives, can spook momentum traders and suggests some tax/liquidity-driven exits or portfolio trimming. Hims & Hers Health (NYSE:HIMS) Insider Sells $258,952.34 in Stock

Analyst Ratings Changes

A number of research firms have recently weighed in on HIMS. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 15th. BTIG Research reaffirmed a “buy” rating and set a $85.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Finally, KeyCorp started coverage on shares of Hims & Hers Health in a research note on Tuesday, October 21st. They set a “sector weight” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $45.50.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtus Advisers LLC bought a new position in shares of Hims & Hers Health during the second quarter worth $26,000. Quent Capital LLC bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $28,000. Quaker Wealth Management LLC purchased a new position in shares of Hims & Hers Health during the second quarter valued at about $29,000. Finally, Bessemer Group Inc. increased its holdings in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.